Objective To assess whether topiramate prevents body weight gain in patients with olanzapine .Methods The ran‐domized controlled trials(RCTs) about topiramate for prevention of weight gain with olanzapine from 1998 to 2013 were searched in the Cochrane Library ,Pubmed ,EMbase ,WanFang Data ,CNKI and VIP .Two reviewers independently screened the literatures ,ex‐tracted the data ,and evaluated the methodological quality .Then Meta‐analyses were conducted by using RevMan 5 .1 software .Re‐sults The total of 11 RCTs were included .Among the 549 patients were involved .The results of Meta‐analyses showed that the ef‐ficacy of the topiramate group was superior to that of the control group in lessen body mass with significant difference (MD= -3 .68 ,95% CI:-5 .16- -2 .19 ,Z=4 .86 ,P<0 .01) .Conclusion Topiramate addition therapy is effective in attenuating olanzapine‐induced weight gain .

Objective To study the changes of serum levels of soluble vascular adhesion protein (sVAP-1), hyaluronic acid (HA) in chronic hepatitis C (CHC) patients, to analysis the relationships between serum sVAP-1 and liver function、HA ,to explore the role of sVAP-1 on the pathogenesis of CHC. Method In our research, 88 cases CHC patients were divided into 2 groups,30 cases serum HCV RNA negative (CHC1 gruop)、58 cases serum HCV RNA opsitive (CHC2 gruop);30 cases healthy individuals were enrolled in our research;the serum levels of sVAP-1 and HA were determined by ELISA; Liver function was assayed by automatic biochemistry analyzer;HCV RNA load was measured by real-time polymerase chain reaction (PCR). Results In CHC1,CHC2 and healthy control groups,serum level of sVAP-1 were (112.75 ± 39.00),(154.24 ± 45.88)and (72.23 ± 35.82) ng/mL(F=38.76,P<0.01),respectively; serum level of HA were(87.03 ± 24.95),(132.98 ± 33.54)and (75.07 ± 24.09)ng/mL,respectively (F=47.44,P<0.01);The concentrations of serum sVAP-1、 HA gradually had been increasing with level of ALT (all P<0.05);Especially,significantly positive associations were highly between serum sVAP-1 and ALT 、AST and HA (r=0.711、0.628、0.816, all P<0.001). Conclusion Serum sVAP-1 may be closely related to the hepatic cell inflammatory injury and liver fibrosis in CHC patients.

Objective To investigate the effect of perfusion index of the injection flow rate of contrast medium on magnetic resonance image dynamic contrast-enhanced (DCE-MRI) of prostate cancer with different pathological grades. Methods Seventy patients with PCa、cardiac, normal renal function is and BMI≤25 kg/m2 were enrolled. The 2.5 mL/s, 5.0 mL/s dynamic enhanced injection velocity contrast agent was used for 35 patients and the reast 35 patients, respectively. All data was transferred to GE Advanced Workstation 4.3, and the indexes of the peripheral prostate cancerous zone were calculated by Functool2 of signal intensity time (SI-T), The time to minimum (Tmax), the whole enhancement degree (SImax%) and the maximum slope (Rmax) were calculated. The effect of different injection velocity on the dynamic enhanced perfusion index was analyzed. Results Tmax of pa-tients received 2.5 mL/s, 5.0 mL/s contrast agent injection velocity in the low risk group (Gleason score 2 to 6)、medium risk group (7 Gleason score) and high risk group (Gleason score 8 to 10) were (19.89 ± 2.76) s and (15.42 ± 1.68) s, (16.91 ± 2.34) s and (12.88 ± 1.73) s, (14.13 ± 1.81) s and (10.2 ± 1.42) s, with signifi-cant differences (t = 4.61, 3.1, 3.25, P < 0.01). The average SImax% of PCa in the two groups were (1.45 ± 0.17)%and (1.51 ± 0.27)%, (1.62 ± 0.12)%and (1.84 ± 0.18)%, (1.86 ± 0.16)% and (2.11 ± 0.28)%, Two groups of SImax% were statistically significant difference (t = -2.44, -4.55, -5.16, P < 0.05), respectively. The average Rmax of PCa of the two groups were (6.29 ± 2.62)% and (7.64 ± 4.09)%,(8.92 ± 4.21)% and (10.24 ± 9.09)%, (10.85 ± 2.89)% and (12.43 ± 3.51)%, with significant difference (t = -4.07,-3.85, -8.68, P <0.01). Tmax was shorter, SImax% and Rmax were higher of prostate cancer patients received 5.0 mL/s contrast agent injection velocity than those received 2.5 mL/s contrast agent injection velocity. Conclusion The dynamic enhancement perfusion index of prostate cancer patients received 5.0 mL/s contrast agent injection velocity is more sensitive than that of patients received 2.5 mL/s contrast agent injection velocity , which can improve the diagnosis of prostate cancer.

Aim To study the effects of pyrin recombi-nant protein ( PRP ) on VEGF/VEGFR2/ MMP-9 sig-naling pathway in bleomycin-induced pulmonary fibro-sis of rats. Methods Sixty male Wistar rats were ran-domly divided into groups of control ( n=10 ) , model ( n=20 ) , PRP ( n=20 ) , and SU5416 ( n=10 ) . All the rats, except for those in control group, were estab-lished as the model of interstitial pulmonary fibrosis by perfusion of bleomycin (5 mg·kg-1 ) through tracheal intubation. From the second day after modeling, all rats were intragastrically administered with drugs or sa-line, according to different groups designed. The rats were sacrificed on the 14th and 28th day, and lung samples were taken out. The pathological changes of interstitial pulmonary fibrosis were observed by HE staining and Masson staining to evaluate the degree of alveolitis and pulmonary fibrosis. Expressions of VEGF, VEGFR2, MMP-9 protein and mRNA were de-tected by immunohistochemistry and RT-PCR. Results On the 14th and 28th day, the alveolitis, pulmonary fibrosis, expression of VEGF, VEGFR2, MMP-9 and mRNA increased significantly in the model group com-pared with in the control group ( P <0. 05 ) , and de-creased significantly in PRP group than those in the model group ( P <0. 05 ) . Conclusion PRP plays a role of anti-pulmonary fibrosis via the down-regulation of VEGF/VEGFR2/MMP-9 signaling pathway.

Objective To investigate the effect of repetitive transcranial magnetic stimulation (rTMS) on social function and life quality of schizophrenia in long-term hospitalization.Methods Sixty patients met with ICD-10 for schizophrenia in long-term hospitalization were enrolled in this study.The group was divided randomly into research (n =40) and control (n =40) groups.They were given rTMS or sham stimulation,respectively.The treatment was given 20 times,and the course of treatment was 4 weeks.The research and control groups were assessed with measured the scale of social function in psychosis inpatients and personal and social function scale and schizophrenia quality of life scale before and'after 4 weeks treatment.Each test result of all groups before and after treatment was compared with each other,respectively.Results Compared to rTMS before treatment,the study group scale of social function in psychosis inpatients (SSPI) total score,factor Ⅰ,Ⅱ and personal and social function scale (PSP) scores were significantly increased (P ＜ 0.05),no change of SSPI factor (P ＞ 0.05);the study group Schizophrenia Quality of Life Scale (SQLS) total score,psychological and social power,the energy scale scores were significantly reduced (P ＜ 0.05),SQLS symptoms and side effects scale showed no significant difference (P ＞ 0.05).No significant change was found in the scores of project SSPI,PSP and SQLS in control group before and after treatment (P ＞ 0.05);the difference of each parameter between two groups after treatment were statistically significant (P ＜ 0.05).Conclusions Repetitive transcranial magnetic stimulation could improve on social function and life quality of schizophrenia in long-term hospitalization,rTMS could provide a new way for the individual rehabilitation of schizophrenia in long-term hospitalization.